spacer
home > ebr > autumn 2017 > firing up
PUBLICATIONS
European Biopharmaceutical Review

Firing Up

Recent advances in immunotherapy, with the discovery of checkpoint inhibitors, have revolutionised the treatment of cancer. The key importance of the interplay between tumours and immune cells is now coming to the forefront. How cancer cells interact with the immune microenvironment is an area of rapidly expanding knowledge. The role of endogenous and exogenous DNA damage in activating the innate and adaptive immune response (IR) is becoming more significant – for example, using exogenous DNA damaging agents to prime the immune system or using endogenous DNA damage response deficiency (DDRD) as a potential biomarker to identify patients for immunotherapies.

Chemotherapy and IR

Although DNA-damaging agents were designed to directly target cancer cells, their interaction with the immune system now recognisably contributes to chemotherapy responses (1). This was first noticed in the 1970s when studies of the mechanism of action of anthracyclines suggested an immune component was involved in response to these agents, with an improved reaction in immuno-competent compared to immuno-compromised mice (2).

DNA-damaging agents such as anthracyclines and oxaliplatin are now known to induce immunogenic cell death through a threestage process. First, calreticulin is expressed on the surface of dying cells – an ‘eat me’ signal – leading to phagocytosis of dying tumour cells by dendritic cells. Next, adenosine triphosphate, released by dying cancer cells, recruits more dendritic cells to the tumour site, resulting in mature dendritic cells with specific major histocompatibility complex (MHC) Class 1 and 2 for the tumour cells. Finally, the release of high mobility group box protein 1 (HMGB1) from the nucleus binds to toll-like receptor 4 (TLR4) on dendritic cells and produces improved crosspresentation of tumour antigens.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Eileen Parkes is an academic clinical lecturer at Queen's University Belfast, Northern Ireland. She completed her PhD on the IR to DNA damage, identifying constitutive activation of the STING immune pathway in endogenous DNA damage by investigating the biology underpinning the DDRD subgroup. She is also a specialist in medical oncology at the Northern Ireland Cancer Centre.

Dr Nuala McCabe graduated from Queen’s University Belfast, Northern Ireland, in 1997 with an honours degree in biomedical science. She then gained her PhD training in the Department of Oncology at Queen’s University Belfast in 2001, investigating the role of the BRCA1 tumour suppressor in DNA damage response. Following this, Nuala then worked as a postdoctoral researcher with Professor Alan Ashworth in the Breakthrough Breast Cancer Research Centre (Institute of Cancer Research, London). During this time, she was involved in the identification of PARP1 inhibitors for the treatment of BRCA-associated breast and ovarian cancers, which are now approved by the EMA.

Professor Richard Kennedy is the Medical Director of Almac Diagnostics and CLIACompliant Laboratory Director. He is responsible for the application of the company’s technology into medical practice. Richard graduated in medicine from Queen’s University Belfast, Northern Ireland, in 1995. As a postgraduate, he trained as a medical oncologist and received a PhD in molecular biology in 2004.

spacer
Dr Eileen Parkes
spacer
spacer
spacer
Dr Nuala McCabe
spacer
spacer
spacer
Professor Richard Kennedy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Synpromics expands facilities to meet demand for revolutionary gene control technology

Edinburgh, UK, 11th September 2017 - Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus.
More info >>

White Papers

galenIQ - The smart excipient

BENEO-Palatinit GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 
Industry Events

13th Annual Biomarkers Congress

15-16 February 2018, Manchester Central Convention Complex, Manchester, UK

Oxford Global is proud to present the 13th Annual Biomarkers Congress to be held on 15-16 February 2018, Manchester. The congress covers novel developments in biomarker discovery and validation, translation into the clinic, personalised healthcare, Big data management, clinical diagnostics development. Key therapeutic focus areas include Immuno Oncology, Neuroscience, Respiratory, Metabolic and Cardiovascular Diseases
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement